(September 12, 2022, 1:52 PM EDT) -- ALEXANDRIA, Va. — In a Sept. 9 petition for inter partes review of a Regeneron Pharmaceuticals Inc. patent directed to a treatment for age-related macular degeneration (AMD), Apotex Inc. asserts that “the caselaw . . . is clear,” in that “it is not patentable to merely observe the efficacy of administering a known compound using a known method to treat a known condition.”...